Scholar Rock Holding Corp

Insider trading at Scholar Rock: Qatanani’s 7% sale under a Rule 10b‑5‑1 plan signals modest portfolio rebalancing amid a shift toward commercialization, but its price just below the prior close may hint at strategic capital planning and impact inve…

Scholar Rock insiders buy shares as executives signal confidence in its gene‑therapy pipeline and future market gains.

Insider sale by Scholar Rock’s CSO shows routine trading amid volatile biotech metrics; analyze the impact on investor sentiment and pipeline confidence.

Scholar Rock insider buying shows confidence in its cancer‑and‑neurodegenerative pipeline, backed by solid Phase 2b safety data and a clear regulatory path.

Scholar Rock CFO’s tax‑cover sale of 16,755 shares shows disciplined equity strategy, confirming leadership’s long‑term alignment while boosting investor confidence in the biotech’s growth pipeline.